Alejandro Bruna-Mejias, Vicente Baeza, Javiera Gamboa, Belen Baez Flores, Jessica San Martin, Constanza Astorga, Javiera Leyton, Pablo Nova-Baeza, Mathias Orellana-Donoso, Alejandra Suazo-Santibañez, Alvaro Becerra-Farfán, Gustavo Oyanedel-Amaro, Juan Jose Valenzuela-Fuenzalida
{"title":"氯胺酮在多因素神经病理性疼痛患者中的应用:系统回顾与元分析。","authors":"Alejandro Bruna-Mejias, Vicente Baeza, Javiera Gamboa, Belen Baez Flores, Jessica San Martin, Constanza Astorga, Javiera Leyton, Pablo Nova-Baeza, Mathias Orellana-Donoso, Alejandra Suazo-Santibañez, Alvaro Becerra-Farfán, Gustavo Oyanedel-Amaro, Juan Jose Valenzuela-Fuenzalida","doi":"10.3390/ph17091165","DOIUrl":null,"url":null,"abstract":"<p><p>Neuropathic pain (NP) is a heterogeneous group of conditions characterized by the experience of a number of sensory disturbances including pain, burning sensations, paroxysms of stabbing pain, dysesthesias, allodynia, and hyperalgesia. The above-mentioned sensations may occur in a specific dermatome area or other delimited region of the body. The objective of this review was to analyze the evidence for ketamine in multifactorial neuropathic pain. The research group systematically searched the databases MEDLINE (via PubMed), EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature (Cinahl), and the Web of Science. The findings of this review show that different forms of low doses of ketamine (LDK) do not present statistically significant changes for any of the scales included. In this study, the total symptom score [standardized mean difference (SMD) = -3.59, confidence interval (CI) = -4.16 to -3.02, and <i>p</i> < 0.00001], neuropathy impairment score (SMD = -1.42, CI = -3.68 to 0.84, and <i>p</i> = 0.22), and neuropathy symptom checklist (SMD = -0.09, CI = -0.15 to -0.02, and <i>p</i> = 0.01) were taken into account. For finality compared to the use of a placebo, the findings suggest that LDK does not exhibit significant differences in terms of pain reduction and functionality. Moreover, no specific dosages are identified to support the use of LDK in the reduction in NP.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11435086/pdf/","citationCount":"0","resultStr":"{\"title\":\"Use of Ketamine in Patients with Multifactorial Neuropathic Pain: A Systematic Review and Meta-Analysis.\",\"authors\":\"Alejandro Bruna-Mejias, Vicente Baeza, Javiera Gamboa, Belen Baez Flores, Jessica San Martin, Constanza Astorga, Javiera Leyton, Pablo Nova-Baeza, Mathias Orellana-Donoso, Alejandra Suazo-Santibañez, Alvaro Becerra-Farfán, Gustavo Oyanedel-Amaro, Juan Jose Valenzuela-Fuenzalida\",\"doi\":\"10.3390/ph17091165\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Neuropathic pain (NP) is a heterogeneous group of conditions characterized by the experience of a number of sensory disturbances including pain, burning sensations, paroxysms of stabbing pain, dysesthesias, allodynia, and hyperalgesia. The above-mentioned sensations may occur in a specific dermatome area or other delimited region of the body. The objective of this review was to analyze the evidence for ketamine in multifactorial neuropathic pain. The research group systematically searched the databases MEDLINE (via PubMed), EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature (Cinahl), and the Web of Science. The findings of this review show that different forms of low doses of ketamine (LDK) do not present statistically significant changes for any of the scales included. In this study, the total symptom score [standardized mean difference (SMD) = -3.59, confidence interval (CI) = -4.16 to -3.02, and <i>p</i> < 0.00001], neuropathy impairment score (SMD = -1.42, CI = -3.68 to 0.84, and <i>p</i> = 0.22), and neuropathy symptom checklist (SMD = -0.09, CI = -0.15 to -0.02, and <i>p</i> = 0.01) were taken into account. For finality compared to the use of a placebo, the findings suggest that LDK does not exhibit significant differences in terms of pain reduction and functionality. Moreover, no specific dosages are identified to support the use of LDK in the reduction in NP.</p>\",\"PeriodicalId\":20198,\"journal\":{\"name\":\"Pharmaceuticals\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11435086/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/ph17091165\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph17091165","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
摘要
神经病理性疼痛(NP)是一类以疼痛、烧灼感、阵发性刺痛、痛觉障碍、异痛症和痛觉减退等多种感觉障碍为特征的疾病。上述感觉可能发生在特定的皮部区域或身体的其他限定区域。本综述旨在分析氯胺酮治疗多因素神经病理性疼痛的证据。研究小组系统地检索了MEDLINE(通过PubMed)、EMBASE、SCOPUS、Cochrane对照试验中央登记册、护理与联合健康文献累积索引(Cinahl)和Web of Science等数据库。综述结果表明,不同形式的低剂量氯胺酮(LDK)对所包含的任何量表都没有统计学意义上的显著变化。在本研究中,症状总分[标准化均值差异(SMD)=-3.59,置信区间(CI)=-4.16至-3.02,p < 0.00001]、神经病变损伤评分(SMD =-1.42,CI =-3.68至0.84,p = 0.22)和神经病变症状核对表(SMD =-0.09,CI =-0.15至-0.02,p = 0.01)均被考虑在内。最后,与使用安慰剂相比,研究结果表明,LDK 在减轻疼痛和提高功能方面没有表现出显著差异。此外,没有发现支持使用 LDK 减少 NP 的特定剂量。
Use of Ketamine in Patients with Multifactorial Neuropathic Pain: A Systematic Review and Meta-Analysis.
Neuropathic pain (NP) is a heterogeneous group of conditions characterized by the experience of a number of sensory disturbances including pain, burning sensations, paroxysms of stabbing pain, dysesthesias, allodynia, and hyperalgesia. The above-mentioned sensations may occur in a specific dermatome area or other delimited region of the body. The objective of this review was to analyze the evidence for ketamine in multifactorial neuropathic pain. The research group systematically searched the databases MEDLINE (via PubMed), EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature (Cinahl), and the Web of Science. The findings of this review show that different forms of low doses of ketamine (LDK) do not present statistically significant changes for any of the scales included. In this study, the total symptom score [standardized mean difference (SMD) = -3.59, confidence interval (CI) = -4.16 to -3.02, and p < 0.00001], neuropathy impairment score (SMD = -1.42, CI = -3.68 to 0.84, and p = 0.22), and neuropathy symptom checklist (SMD = -0.09, CI = -0.15 to -0.02, and p = 0.01) were taken into account. For finality compared to the use of a placebo, the findings suggest that LDK does not exhibit significant differences in terms of pain reduction and functionality. Moreover, no specific dosages are identified to support the use of LDK in the reduction in NP.